RxDoctor Payments Data

Christina Bach, MD

Pulmonary Disease · Rochester, NYNPI 1396164174

Payments from drug & device makers

$53,425in general payments, 2019–2025

Across 158 payments — averaging $338.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$52K
  • AstraZeneca$295
  • Amgen$159
  • Actelion Pharmaceuticals US, Inc.$109
  • Sanofi$94
  • Grifols USA, LLC$91
  • plus $406 from 10 others

What the payments were for

  • Speaking & faculty fees$48,42591%
  • Travel & lodging$1,1102%
  • Food & beverage$3,8727%
  • Gifts$170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,425 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$31,747
Medicare patients
124
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter230$167,000
Fasenra PenBenralizumab14$79,799
NucalaMepolizumab19$70,331
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr94$47,109
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$45,540
Breo ElliptaFluticasone/Vilanterol84$34,436
Stiolto RespimatTiotropium Br/Olodaterol Hcl57$29,436
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$10,040
Wixela InhubFluticasone Propion/Salmeterol35$5,843
SymbicortBudesonide/Formoterol Fumarate18$4,070
Albuterol Sulfate HfaAlbuterol Sulfate100$3,228
Azelastine Hcl32$702
Roflumilast11$443
Prednisone43$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta$52,271$318,875427 claims
AstraZenecaBreztri Aerosphere, Symbicort$295$49,61079 claims
Boehringer IngelheimStiolto Respimat$69$29,43657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →